These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Multi-omics study reveals that statin therapy is associated with restoration of gut microbiota homeostasis and improvement in outcomes in patients with acute coronary syndrome. Hu X; Li H; Zhao X; Zhou R; Liu H; Sun Y; Fan Y; Shi Y; Qiao S; Liu S; Liu H; Zhang S Theranostics; 2021; 11(12):5778-5793. PubMed ID: 33897881 [No Abstract] [Full Text] [Related]
3. Alterations of Gut Microbiome and Serum Metabolome in Coronary Artery Disease Patients Complicated With Non-alcoholic Fatty Liver Disease Are Associated With Adverse Cardiovascular Outcomes. Hu X; Zhou R; Li H; Zhao X; Sun Y; Fan Y; Zhang S Front Cardiovasc Med; 2021; 8():805812. PubMed ID: 35047580 [No Abstract] [Full Text] [Related]
4. Association of Coronary Artery Disease and Metabolic Syndrome: Usefulness of Serum Metabolomics Approach. Jing Z; Liu L; Shi Y; Du Q; Zhang D; Zuo L; Du S; Sun Z; Zhang X Front Endocrinol (Lausanne); 2021; 12():692893. PubMed ID: 34630321 [TBL] [Abstract][Full Text] [Related]
5. Gut microbiota and metabolomics profiles in patients with chronic stable angina and acute coronary syndrome. Ahmad AF; Caparrós-Martin JA; Gray N; Lodge S; Wist J; Lee S; O'Gara F; Dwivedi G; Ward NC Physiol Genomics; 2024 Jan; 56(1):48-64. PubMed ID: 37811721 [TBL] [Abstract][Full Text] [Related]
7. Correlation of the severity of coronary artery disease with patients' metabolic profile- rationale, design and baseline patient characteristics of the CorLipid trial. Karagiannidis E; Sofidis G; Papazoglou AS; Deda O; Panteris E; Moysidis DV; Stalikas N; Kartas A; Papadopoulos A; Stefanopoulos L; Karvounis H; Gika H; Theodoridis G; Sianos G BMC Cardiovasc Disord; 2021 Feb; 21(1):79. PubMed ID: 33557756 [TBL] [Abstract][Full Text] [Related]
8. The Effects of Moderate Alcohol Consumption on Circulating Metabolites and Gut Microbiota in Patients With Coronary Artery Disease. Zhao X; Zhou R; Li H; Fan Y; Sun Y; Hu X; Zhang S Front Cardiovasc Med; 2021; 8():767692. PubMed ID: 34796220 [No Abstract] [Full Text] [Related]
9. Impact of counterbalance between macrophage migration inhibitory factor and its inhibitor Gremlin-1 in patients with coronary artery disease. Müller II; Müller KA; Karathanos A; Schönleber H; Rath D; Vogel S; Chatterjee M; Schmid M; Haas M; Seizer P; Langer H; Schaeffeler E; Schwab M; Gawaz M; Geisler T Atherosclerosis; 2014 Dec; 237(2):426-32. PubMed ID: 25463068 [TBL] [Abstract][Full Text] [Related]
10. Anxiety disturbs the blood plasma metabolome in acute coronary syndrome patients. Wei H; Gu J; Jiang X; Deng N; Wu J; Zou L; Zhu Y; Tan B Sci Rep; 2021 Jun; 11(1):12897. PubMed ID: 34145340 [TBL] [Abstract][Full Text] [Related]
11. Gut microbiota combined with metabolites reveals unique features of acute myocardial infarction patients different from stable coronary artery disease. Dong C; Yang Y; Wang Y; Hu X; Wang Q; Gao F; Sun S; Liu Q; Li L; Liu J; Tang Y; Zhang S; Wu C; Zhu H J Adv Res; 2023 Apr; 46():101-112. PubMed ID: 35750287 [TBL] [Abstract][Full Text] [Related]
12. A metabolomic view of how the human gut microbiota impacts the host metabolome using humanized and gnotobiotic mice. Marcobal A; Kashyap PC; Nelson TA; Aronov PA; Donia MS; Spormann A; Fischbach MA; Sonnenburg JL ISME J; 2013 Oct; 7(10):1933-43. PubMed ID: 23739052 [TBL] [Abstract][Full Text] [Related]
13. Dysbiosis signatures of gut microbiota in coronary artery disease. Zhu Q; Gao R; Zhang Y; Pan D; Zhu Y; Zhang X; Yang R; Jiang R; Xu Y; Qin H Physiol Genomics; 2018 Oct; 50(10):893-903. PubMed ID: 30192713 [TBL] [Abstract][Full Text] [Related]
14. Untargeted high-resolution plasma metabolomic profiling predicts outcomes in patients with coronary artery disease. Mehta A; Liu C; Nayak A; Tahhan AS; Ko YA; Dhindsa DS; Kim JH; Hayek SS; Sperling LS; Mehta PK; Sun YV; Uppal K; Jones DP; Quyyumi AA PLoS One; 2020; 15(8):e0237579. PubMed ID: 32810196 [TBL] [Abstract][Full Text] [Related]
15. Identification of Metabolites Associated with Onset of CAD in Diabetic Patients Using CE-MS Analysis: A Pilot Study. Omori K; Katakami N; Yamamoto Y; Ninomiya H; Takahara M; Matsuoka TA; Bamba T; Fukusaki E; Shimomura I J Atheroscler Thromb; 2019 Mar; 26(3):233-245. PubMed ID: 30068816 [TBL] [Abstract][Full Text] [Related]
16. Angiographic severity of coronary artery disease and cardiovascular risk in acute coronary syndrome in patients with metabolic syndrome. Widecka K; Safranow K; Lewandowski M; Przybycień K; Gorący J; Kornacewicz-Jach Z Kardiol Pol; 2018; 76(3):662-668. PubMed ID: 29297191 [TBL] [Abstract][Full Text] [Related]
17. A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action: The similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin. Zhang C; Ma S; Wu J; Luo L; Qiao S; Li R; Xu W; Wang N; Zhao B; Wang X; Zhang Y; Wang X Pharmacol Res; 2020 Sep; 159():104985. PubMed ID: 32504839 [TBL] [Abstract][Full Text] [Related]